<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941665</url>
  </required_header>
  <id_info>
    <org_study_id>5652-18-SMC</org_study_id>
    <nct_id>NCT03941665</nct_id>
  </id_info>
  <brief_title>Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients</brief_title>
  <official_title>Double Blind Study - Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of Gelronate gel, NaHA based product (medical
      device for topical application) vs. Aloevera gel, in prevention or minimizing of radiation
      induced skin reaction in breast cancer patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gelronate is gel composed of 1% high molecular weight pharmaceutical grade sodium hyaluronate
      and preservatives dissolved in pharmaceutical grade purified water. Gelronate supply in an
      airless pump bottle contain ~30 ml gel. In the study, 120 female patients planned to receive
      whole breast radiation (with or without lymphatic drainage) in the radiotherapy unit at Sheba
      Medical Center.

      Patients will undergo CT simulation with 3D treatment planning (as routine done) and will
      receive 42.4 Gy in daily fraction of 2.65 Gy, five times per week to the whole breast
      according to the standard department protocol, with or without concomitant or subsequent
      lumpectomy cavity boost. Patients data including demographics, staging, systemic therapy,
      radiation details, other medications will be recorded the protocol's forms.

      The gel will be applied as a thin lotion twice a day, immediately after radiotherapy
      treatment and once more in the evening/morning. The therapy will continue for 10 days
      following the end of radiation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Development and degree of any skin reaction</measure>
    <time_frame>4 weeks</time_frame>
    <description>Grading according to Radiation Toxicity Grading (RTOG) skin toxicity score. Full scale of RTOG is 0 (no change over baseline) to 4 (ulceration, hemorrhage, necrosis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development and degree of any skin reaction</measure>
    <time_frame>4 weeks</time_frame>
    <description>Assessment of skin reaction by scoring of weekly digital photographs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development and degree of any skin reaction</measure>
    <time_frame>4 weeks</time_frame>
    <description>Patient comfort assessed by weekly administrated questionnaire. Scores are between 1 (nothing) to 4 (all over the breast)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin reaction requiring conventional topical therapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Skin reaction requiring conventional topical therapy (e.g. steroid cream etc.) as evaluated by clinical. judgment of radiotherapy nurse/radiation oncologist at OTV (on treatment view visit that will include RTOG (Radiation Toxicity Grading) scores (in the range 0 no change to 4 ulceration, hemorrhage, necrosis) and dermatology assessment according to the table in the protocol (general view range 1 (nothing) to 4 (continuous))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>Gelronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tested new medical device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aloevera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Current product used by the medical center</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelronate</intervention_name>
    <description>Gel for topical use</description>
    <arm_group_label>Aloevera</arm_group_label>
    <arm_group_label>Gelronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aloevera</intervention_name>
    <description>Gel for topical use</description>
    <arm_group_label>Aloevera</arm_group_label>
    <arm_group_label>Gelronate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients aged at least 18 years with unilateral breast following lumpectomy +/-
             chemotherapy

          -  Planned to receive 42.4 Gy whole breast irradiation +/- boost to tumor bed.

          -  ECOG performance status 0-2.

          -  Capable of giving written informed consent.

          -  No co-morbidities known to affect radiotherapy reactions.

          -  No co-existing acute or chronic skin disease.

          -  No evidence of infection or inflammation of breast to be treated.

          -  Not receiving chemotherapy during radiotherapy course. Biological therapy (e.g.
             Herceptin) or hormone therapy will be allowed during the study.

        Exclusion Criteria:

          -  Chemotherapy within 4 weeks prior to planned start of radiation or chemotherapy
             planned during radiation.

          -  Prior radiotherapy to the chest wall.

          -  Collagen vascular disease.

          -  Participation in other clinical study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofer S Dubinsky, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Holding Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Primavera G, Carrera M, Berardesca E, Pinnar√≥ P, Messina M, Arcangeli G. A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (XClair), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis. Cutan Ocul Toxicol. 2006;25(3):165-71.</citation>
    <PMID>16980242</PMID>
  </results_reference>
  <results_reference>
    <citation>Leonardi MC, Gariboldi S, Ivaldi GB, Ferrari A, Serafini F, Didier F, Mariani L, Castiglioni S, Orecchia R. A double-blind, randomised, vehicle-controlled clinical study to evaluate the efficacy of MAS065D in limiting the effects of radiation on the skin: interim analysis. Eur J Dermatol. 2008 May-Jun;18(3):317-21. doi: 10.1684/ejd.2008.0396. Epub 2008 May 13.</citation>
    <PMID>18474463</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03941665/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

